3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
34
Lung Neoplasms
9
Neoplasms
6
Neoplasm Metastasis
5
Carcinoma
5
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Noonan Syndrome
1
Non Small Cell Lung Cancer Metastatic
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
NSCLC
1
Multiple Myeloma
1
Lymphoma
1
Lung Diseases
1
Locally Advanced or Metastatic EGFR T790M+ NSCLC
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
Sunitinib
64
Nivolumab
42
pembrolizumab
36
Bevacizumab
32
Everolimus
31
Sorafenib
25
pazopanib
23
Axitinib
23
cabozantinib
14
aldesleukin
13
Ipilimumab
13
temsirolimus
11
Interferon alpha-2
11
Cyclophosphamide
10
avelumab
9
Magnetic Resonance Spectroscopy
9
Interleukin-2
9
lenvatinib
8
atezolizumab
8
Radiosurgery
8
Gemcitabine
8
Immunoglobulin G
7
Erlotinib Hydrochloride
7
Disulfides
6
fludarabine phosphate
5
Radiotherapy
5
Fluorodeoxyglucose F18
5
peginterferon alfa-2b
4
Vorinostat
4
Tyrosine Kinase Inhibitors
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Renal Cell
×
osimertinib
×
Clear all
No trials found.